J2KBIO Co., Ltd. (420570) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of J2KBIO Co., Ltd. stock KRW 10,056, price KRW 7,820, upside +28.6%, quality 56 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
32‑month range 6,950 KRW – 32,488 KRW · fair‑value band 6,884 KRW – 12,570 KRW · the 7,820 KRW price screens below the 10,056 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow J2KBIO Co. in your weekly email
Every Wednesday you see whether J2KBIO Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
J2KBIO Co., Ltd., a bio venture company, offers active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation. The company was founded in 2014 and is based in Cheongju, South Korea.
Stock analysis
J2KBIO Co., Ltd. (420570) currently trades at 7,820 KRW, while our model-based Fair Value estimate is 10,056 KRW, implying the stock looks roughly 22% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 11,718 KRW per share, and 17 of the 26 models we run sit above the 7,820 KRW price.
Bear case: the Asset-Based group reads lowest at 3,019 KRW, and 9 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 6,884 KRW (bear) to 12,570 KRW (bull), the price of 7,820 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Basic Materials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
J2KBIO Co., Ltd. reported revenue of 33.0B KRW in FY2025 versus 14.2B KRW in FY2021, a compound +23.4%/yr. Reported net income was 2.7B KRW in FY2025, compounding +13.3%/yr from FY2021.
Key figures
Market cap 45.7B KRW (≈ $33.8M) Micro · P/E ratio 7.8 · P/S ratio 1.02 · EPS (TTM) 994.25 KRW · Dividend yield 3.2% · Net margin 13.2% · Return on equity 16.9% · Return on assets (EBIT) 13.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at 29%, 420570 screens cheaper than that median.
Fair Value models
Bear6,884 KRWFair Value 10,056 KRWBull12,570 KRW
Price 7,820 KRW · Upside +28.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (638.22 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.80/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.2%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.3%
Dividend (yield on the price)3.2%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 9%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +15.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 728 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside+31.1% · Top 25%
Profitability
Return on equity (12 months)16.9% · Top 25%
Return on assets7.0% · Top 25%
Net margin (12 months)13.2% · Top 25%
Operating margin (12 months)17.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)83.0% · Top 25%
Dividend yield (12 months)3.2% · Top 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is J2KBIO Co., Ltd. (420570) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 10,056 KRW versus a price of 7,820 KRW, about +29% upside (undervalued).
What is the fair value of 420570?
Our model-based fair value for J2KBIO Co., Ltd. is 10,056 KRW (as of Nov 4, 2026), built from audited fundamentals. The current price: 7,820 KRW.
What is the quality score of 420570?
J2KBIO Co., Ltd. has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for J2KBIO Co., Ltd. (420570)?
Our model-based price target is the fair value of 10,056 KRW (as of Nov 4, 2026) from 26 valuation models. Cautious scenario 6,884 KRW, optimistic scenario 12,570 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the J2KBIO Co., Ltd. stock forecast for 2026?
Our models put fair value at 10,056 KRW, about +29% upside versus a price of 7,820 KRW (undervalued). Cautious scenario 6,884 KRW, optimistic scenario 12,570 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of J2KBIO Co., Ltd. (420570)?
J2KBIO Co., Ltd. reported trailing-twelve-month revenue of about 43.9B KRW (latest available figure, as of Nov 4, 2026).
Does J2KBIO Co., Ltd. pay a dividend?
J2KBIO Co., Ltd. currently shows a dividend yield of 3.20% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of J2KBIO Co., Ltd. (420570) and when is the ex-dividend date?
J2KBIO Co., Ltd. pays a dividend of 250.00 KRW per share a year, a dividend yield of 3.2%. The last ex-dividend date was Dec 29, 2025. The payout ratio is 25.1% of earnings. Free cash flow covers the dividend 0.65 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into J2KBIO Co., Ltd. (420570)?
For today's price to be fair in a discounted-cash-flow model, J2KBIO Co., Ltd. would have to grow free cash flow by +17.9 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +23.4 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of 420570 use?
Our models discount J2KBIO Co., Ltd. at 8.9 %: a base by market capitalisation (nano), damped by beta 0.33, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For J2KBIO Co., Ltd. that is +17.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has J2KBIO Co., Ltd. (420570) delivered so far?
Over the past 4 years revenue at J2KBIO Co., Ltd. grew +23.4 % a year. The price currently implies free-cash-flow growth of +17.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of J2KBIO Co., Ltd. (420570) growing?
The median revenue growth in the sector is +11.2 % a year. That is the yardstick for the growth priced into J2KBIO Co., Ltd. (+17.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of J2KBIO Co., Ltd. (420570)?
The free-cash-flow yield on the price is 2.06 %: that much free cash flow J2KBIO Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of J2KBIO Co., Ltd. (420570)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For J2KBIO Co., Ltd. it is 10,056 KRW per share (as of Nov 4, 2026), against a price of 7,820 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is J2KBIO Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 420570 trades below its calculated fair value: price 7,820 KRW, fair value 10,056 KRW, a gap of about +29% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 420570?
No. The price is what the market pays today (7,820 KRW); the fair value is what the company's own numbers justify (10,056 KRW). For J2KBIO Co., Ltd. the two are 2,236 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is J2KBIO Co., Ltd. worth?
The market values J2KBIO Co., Ltd. at about 45.7B KRW (market capitalisation, as of Nov 4, 2026). Per share that is 7,820 KRW; our models calculate a fair value of 10,056 KRW per share.
What do the bullish and bearish scenarios say about 420570?
Our models span a range for J2KBIO Co., Ltd.: cautious scenario 6,884 KRW, base 10,056 KRW, optimistic 12,570 KRW per share (as of Nov 4, 2026, price 7,820 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 420570?
J2KBIO Co., Ltd. trades at a price-to-earnings ratio of 7.8 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 10,056 KRW is built from several models across several years. Other multiples: P/B 1.3, P/S 1.0, EV/EBITDA 4.1.
How solid is the balance sheet of J2KBIO Co., Ltd. (420570)?
Balance-sheet figures for J2KBIO Co., Ltd. (as of Nov 4, 2026): return on equity 16.9%, debt of 0.01 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 420570 from its 52-week high?
J2KBIO Co., Ltd. trades at 7,820 KRW, about 35% below its 52-week high of 12,000 KRW and 13% above the low of 6,950 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 10,056 KRW is for.
Which stocks are comparable to J2KBIO Co., Ltd.?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is J2KBIO Co., Ltd. stock attractive at the current price?
The data as of Nov 4, 2026: price 7,820 KRW, calculated fair value 10,056 KRW (+29%), Quality Score 56/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 420570 calculated?
We run J2KBIO Co., Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 10,056 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. J2KBIO Co., Ltd. currently trades 22% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of J2KBIO Co., Ltd. (420570)?
The closing price on Nov 9, 2026 was 7,820 KRW. Our model-based fair value is 10,056 KRW, about +29% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with J2KBIO Co., Ltd. right now?
Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (6,884 KRW to 12,570 KRW) leaves room in how you read the outcome.
Key figures of J2KBIO Co., Ltd.
How large is the market capitalisation of J2KBIO Co., Ltd. (420570)?
The market capitalisation of J2KBIO Co., Ltd. is 45.7B KRW (≈ $33.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of J2KBIO Co., Ltd. (420570)?
The price-to-sales ratio of J2KBIO Co., Ltd. is 1.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of J2KBIO Co., Ltd. (420570)?
Earnings per share at J2KBIO Co., Ltd. are 994.25 KRW (price ÷ EPS = P/E 7.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of J2KBIO Co., Ltd. (420570)?
The dividend yield of J2KBIO Co., Ltd. is 3.2% (payout 25.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of J2KBIO Co., Ltd. (420570)?
The net margin of J2KBIO Co., Ltd. is 13.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of J2KBIO Co., Ltd. (420570)?
The return on equity (ROE) of J2KBIO Co., Ltd. is 16.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of J2KBIO Co., Ltd. (420570)?
On an EBIT basis the return on assets of J2KBIO Co., Ltd. is 13.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of J2KBIO Co., Ltd. (420570)?
The operating margin of J2KBIO Co., Ltd. is 17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at J2KBIO Co., Ltd. (420570)?
Revenue at J2KBIO Co., Ltd. is growing +83.0% versus a year earlier (3y avg +27.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at J2KBIO Co., Ltd. (420570)?
Earnings per share at J2KBIO Co., Ltd. are growing +202% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch J2KBIO Co., Ltd. in the live analysis
One click puts J2KBIO Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 4, 2026